HomeNDC LookupRxCUI directory › RxCUI 1112250

12 HR desloratadine 2.5 MG / pseudoephedrine sulfate 120 MG Extended Release Oral Tablet [... — RxCUI 1112250

RxNorm drug concept · Semantic branded drug
RxCUI 1112250 Semantic branded drug · SBD ● Current RxNorm concept 1 FDA product 1 package NDC Snapshot Jul 14, 2026

What you’re looking at: the standardized identity of one medicine, as the U.S. drug-data system sees it. Below — every FDA-listed product, package code, price benchmark, and billing code that maps to it.

🗂️ Key Facts

RxCUI1112250
Official name12 HR desloratadine 2.5 MG / pseudoephedrine sulfate 120 MG Extended Release Oral Tablet [Clarinex-D]
Concept typeSemantic branded drug (SBD)
RxNorm statusCurrent RxNorm concept
Also known asCLARINEX-D 2.5 MG / 120 MG 12HR Extended Release Oral Tablet
FDA products mapped1
Package NDCs mapped1
Reported Medicaid activity (SDUD)58 prescriptions · 2 state & territory Medicaid programs · latest period Q4 2025
RxNorm release07/06/2026
Snapshot dataJul 14, 2026

📖 Skip the Codes — Read It in Plain English.

Our pharmacist-built guide to Desloratadine: what it is, how it’s used, side effects, and interactions.

📗 Our plain-language guide HelloPharmacist
  • Desloratadine is used to relieve allergy symptoms — think sneezing, runny nose, itchy eyes — from both seasonal allergies (like hay fever) and year-round allergies. It also helps w...
  • Desloratadine is far less likely to cause drowsiness than older antihistamines because it doesn't readily cross into the brain. That said, drowsiness was still reported in some pat...
  • Some medications — including the antifungal ketoconazole, the antibiotics erythromycin and azithromycin, the antidepressant fluoxetine, and the acid-reducer cimetidine — can raise...
  • Can I take this with my other medications?
📖 Read our full Desloratadine guide →

🕸️ Concept Web — How 12 HR desloratadine 2.5 MG / pseudoephedrine sul... Connects

One RxCUI never lives alone. Follow the path from the raw ingredient down to the exact strength-and-form concepts FDA products carry — every stop is a real RxNorm concept with its own identifier. Hover or focus any chip for what it means.
This page's concept 12 HR desloratadine 2.5 MG / pseudoephedrine sulfate 120 MG Extended Release Oral Tablet [Clarinex-D] RxCUI 1112250

Every web starts here: one RxCUI, one fixed meaning in the RxNorm vocabulary.

  1. Ingredients 4

    The active substance itself — no strength, form, or brand attached yet.

    • Desloratadine 275635
    • Pseudoephedrine 8896
    • Desloratadine / pseudoephedrine 597501
    • Pseudoephedrine sulfate 91169
  2. Brand names 1

    The same medicine's trade names. A brand name alone says nothing about strength or form.

    • Clarinex-D 579752
  3. Dose forms 13

    The ingredient poured into a form — tablet, solution, cream — still without one fixed strength.

    • Desloratadine / pseudoephedrine Extended Release Oral Tablet 616849
    • Desloratadine / pseudoephedrine sulfate Extended Release Oral Tablet 2648294
    • Desloratadine / pseudoephedrine Oral Product 1157754
    • Desloratadine / pseudoephedrine Pill 1157755
    • Desloratadine / pseudoephedrine sulfate Oral Product 2660618
    • Desloratadine / pseudoephedrine sulfate Pill 2663019
    • Desloratadine / pseudoephedrine Extended Release Oral Tablet [Clarinex-D] 721642
    • Desloratadine / pseudoephedrine sulfate Extended Release Oral Tablet [Clarinex-D] 2658579
    • +5 more in this family
  4. Clinical & branded drugs 4

    Ingredient + strength + dose form. These are the concepts real FDA products actually carry.

Showing up to 8 concepts per family — 17 of 22 stored related concepts drawn.
These are official RxNorm vocabulary relationships — how concepts name and organize the same medicine. They do not establish therapeutic equivalence or substitutability: two concepts appearing in one web is never a statement that products can be swapped.

🔀 Generic ⇄ Brand Crosswalk

The same medicine has an unbranded (generic) identity and one or more brand-name identities — each with its own RxCUI. This is a naming relationship in RxNorm, not a statement that any two products are substitutable.

Generic (Clinical) Concepts

  • 12 HR desloratadine 2.5 MG / pseudoephedrine sulfate 120 MG Extended Release Oral Tablet SCD · 1112248
  • Desloratadine 2.5 MG SCDC · 577079
  • Pseudoephedrine sulfate 120 MG SCDC · 1112247
  • Desloratadine / pseudoephedrine Extended Release Oral Tablet SCDF · 616849
  • Desloratadine / pseudoephedrine sulfate Extended Release Oral Tablet SCDFP · 2648294
  • Desloratadine / pseudoephedrine Oral Product SCDG · 1157754
  • Desloratadine / pseudoephedrine Pill SCDG · 1157755
  • Desloratadine / pseudoephedrine sulfate Oral Product SCDGP · 2660618
  • Desloratadine / pseudoephedrine sulfate Pill SCDGP · 2663019

Brand-Name Concepts

  • Desloratadine 2.5 MG / pseudoephedrine sulfate 120 MG [Clarinex-D] SBDC · 1112249
  • Desloratadine / pseudoephedrine Extended Release Oral Tablet [Clarinex-D] SBDF · 721642
  • Desloratadine / pseudoephedrine sulfate Extended Release Oral Tablet [Clarinex-D] SBDFP · 2658579
  • Clarinex-D Oral Product SBDG · 1171561
  • Clarinex-D Pill SBDG · 1171562
  • Clarinex-D BN · 579752

📦 FDA Products & Package NDCs

1 product · 1 package NDC
1 package NDC map to RxCUI 1112250 in the current snapshot — up to 50 per page. Each linked NDC opens its full package page.
Package NDC Package Brand / generic name Labeler Marketing start
78206-0120-01 100 TABLET, EXTENDED RELEASE in 1 BOTTLE, PLASTIC (78206-120... CLARINEX-D 12 HOUR Organon LLC 2021-06-01
Observed labelers: Organon LLC (1) — this is the FDA-listed mapping footprint, not sales, inventory, availability, or market share.

💲 Pricing (NADAC)

NADAC is CMS's National Average Drug Acquisition Cost — roughly what pharmacies pay to buy the drug. It is an acquisition benchmark, not your copay.
Per ea · median
$6.0699
Range $6.0699–$6.0699 · middle 50% $6.0699–$6.0699 · 1 NDCs
Latest compatible distributions from the CMS NADAC file · dataset watermark 2026-07-10. Prices vary by package and pharmacy; a distribution is shown instead of one misleading number. Rows the dataset is silent on carry no price. No zero-cost conclusion should be drawn.

🗃️ Sources & Limits

Atlas generation902fddb9-e9c1-4004-bf4c-dba4d51037c7
openFDA export observedJul 14, 2026
RxNorm release07/06/2026
Methodology2026-07-full-catalog-v1
  • A shared RxCUI does not prove interchangeability. Products mapped to the same concept are not thereby equivalent or substitutable — equivalence is a separate, product-level determination.
  • Listing here does not establish approval or coverage. Appearing in this snapshot is a data observation, not an FDA approval status or a payer coverage decision.
  • Missing data never means zero. A silent dataset (no price, no billing code, no utilization) means no observation — not that the real-world value is zero.
  • Counts describe the mapping footprint. Product, package, and labeler counts are the FDA-listed mapping footprint in this snapshot — not sales, inventory, availability, or market share.
This product uses publicly available data from the U.S. National Library of Medicine (NLM), National Institutes of Health, Department of Health and Human Services; NLM is not responsible for the product and does not endorse or recommend this or any other product.

Machine-readable JSON

Reference information about drug-concept identifiers and public regulatory data — not medical advice. Talk to your pharmacist or prescriber about your own medication.